Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects

Activation of the brain dopamine D1 receptor has attracted attention because of its promising role in neuropsychiatric diseases. Although efforts to develop D1 agonists have been challenging, a positive allosteric modulator (PAM), represents an attractive approach with potential better drug‐like pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilbraham, Darren, Biglan, Kevin M., Svensson, Kjell A., Tsai, Max, Kielbasa, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048550/
https://www.ncbi.nlm.nih.gov/pubmed/33029934
http://dx.doi.org/10.1002/cpdd.874

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048550/
https://www.ncbi.nlm.nih.gov/pubmed/33029934
http://dx.doi.org/10.1002/cpdd.874

Ejemplares similares